Antitumor activity and downregulation of pro-angiogenic molecules in human prostate cancer cells by a novel thiazolidione compound

Fuminori Teranishi, Shuhong Wu, Satoshi Inoue, Lidong Zhang, John J. Davis, Wei Guo, Fengqin Dong, Bingliang Fang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

BACKGROUND. Current treatments for prostate cancer are effective in many patients with locally advanced disease, but many of these patients eventually have recurrence. It is therefore important to develop alternative therapeutic agents with improved efficacy and tolerability. We recently identified a synthetic thiazolidin compound, 5-(2,4-dihydroxybenzylidene)-2-(phenylimino)-1, 3-thiazolidione (DBPT), that induces apoptosis in human colon cancer cells, independent of p53 and P-glycoprotein status. Here, we investigated the antitumor properties and mechanisms of action of this compound in human prostate cancer cell lines. METHODS. The effect of DBPT on cell-cycle progression and apoptosis in LNCaP and DU145 cells was examined by flow cytometry and Western blotting. The effect of DBPT on pro-angiogenic molecules was analyzed by Western blotting and by an enzyme-linked immunosorbent assay. RESULTS. DBPT inhibited the growth of LNCaP and DU145 cells with 50% inhibitory concentrations ranging from 1.6 to 5.9 μM. Treating LNCaP and DU145 cells with DBPT led to a time-dependent cell-cycle arrest in the G2/M phase and increased levels of G2/M checkpoint proteins, such as cyclin B1, cdc25C, phosphorylated histone H3, and MPM-2. DBPT induced the phosphorylation of Bcl-xL and Bim, and induced apoptosis, as evidenced by cleavage of caspase and poly (ADP-ribose) polymerase. DBPT also effectively induced apoptosis in Bcl-2-overexpressing DU145 cells. Furthermore, DBPT decreased hypoxia-inducible factor 1α and vascular endothelial growth factor expression in LNCaP cells under both normoxia and hypoxia. CONCLUSIONS. DBPT can suppress proliferation, induce apoptosis, and downregulate pro-angiogenic molecules in prostate cancercells, and might be useful in treating prostate cancer.

Original languageEnglish
Pages (from-to)430-438
Number of pages9
JournalProstate
Volume66
Issue number4
DOIs
Publication statusPublished - Mar 1 2006
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Down-Regulation
Apoptosis
Western Blotting
Cyclin B1
Hypoxia-Inducible Factor 1
Poly(ADP-ribose) Polymerases
G2 Phase
P-Glycoprotein
Caspases
Cell Cycle Checkpoints
Cell Division
Histones
Colonic Neoplasms
Vascular Endothelial Growth Factor A
Inhibitory Concentration 50
Prostate
Cell Cycle
Flow Cytometry
Enzyme-Linked Immunosorbent Assay

Keywords

  • Apoptosis
  • G/M-phase arrest
  • Novel compound
  • Prostate cancer
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Antitumor activity and downregulation of pro-angiogenic molecules in human prostate cancer cells by a novel thiazolidione compound. / Teranishi, Fuminori; Wu, Shuhong; Inoue, Satoshi; Zhang, Lidong; Davis, John J.; Guo, Wei; Dong, Fengqin; Fang, Bingliang.

In: Prostate, Vol. 66, No. 4, 01.03.2006, p. 430-438.

Research output: Contribution to journalArticle

Teranishi, Fuminori ; Wu, Shuhong ; Inoue, Satoshi ; Zhang, Lidong ; Davis, John J. ; Guo, Wei ; Dong, Fengqin ; Fang, Bingliang. / Antitumor activity and downregulation of pro-angiogenic molecules in human prostate cancer cells by a novel thiazolidione compound. In: Prostate. 2006 ; Vol. 66, No. 4. pp. 430-438.
@article{7e0abbc6d36e42f885024cb68a10f7d0,
title = "Antitumor activity and downregulation of pro-angiogenic molecules in human prostate cancer cells by a novel thiazolidione compound",
abstract = "BACKGROUND. Current treatments for prostate cancer are effective in many patients with locally advanced disease, but many of these patients eventually have recurrence. It is therefore important to develop alternative therapeutic agents with improved efficacy and tolerability. We recently identified a synthetic thiazolidin compound, 5-(2,4-dihydroxybenzylidene)-2-(phenylimino)-1, 3-thiazolidione (DBPT), that induces apoptosis in human colon cancer cells, independent of p53 and P-glycoprotein status. Here, we investigated the antitumor properties and mechanisms of action of this compound in human prostate cancer cell lines. METHODS. The effect of DBPT on cell-cycle progression and apoptosis in LNCaP and DU145 cells was examined by flow cytometry and Western blotting. The effect of DBPT on pro-angiogenic molecules was analyzed by Western blotting and by an enzyme-linked immunosorbent assay. RESULTS. DBPT inhibited the growth of LNCaP and DU145 cells with 50{\%} inhibitory concentrations ranging from 1.6 to 5.9 μM. Treating LNCaP and DU145 cells with DBPT led to a time-dependent cell-cycle arrest in the G2/M phase and increased levels of G2/M checkpoint proteins, such as cyclin B1, cdc25C, phosphorylated histone H3, and MPM-2. DBPT induced the phosphorylation of Bcl-xL and Bim, and induced apoptosis, as evidenced by cleavage of caspase and poly (ADP-ribose) polymerase. DBPT also effectively induced apoptosis in Bcl-2-overexpressing DU145 cells. Furthermore, DBPT decreased hypoxia-inducible factor 1α and vascular endothelial growth factor expression in LNCaP cells under both normoxia and hypoxia. CONCLUSIONS. DBPT can suppress proliferation, induce apoptosis, and downregulate pro-angiogenic molecules in prostate cancercells, and might be useful in treating prostate cancer.",
keywords = "Apoptosis, G/M-phase arrest, Novel compound, Prostate cancer, VEGF",
author = "Fuminori Teranishi and Shuhong Wu and Satoshi Inoue and Lidong Zhang and Davis, {John J.} and Wei Guo and Fengqin Dong and Bingliang Fang",
year = "2006",
month = "3",
day = "1",
doi = "10.1002/pros.20373",
language = "English",
volume = "66",
pages = "430--438",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Antitumor activity and downregulation of pro-angiogenic molecules in human prostate cancer cells by a novel thiazolidione compound

AU - Teranishi, Fuminori

AU - Wu, Shuhong

AU - Inoue, Satoshi

AU - Zhang, Lidong

AU - Davis, John J.

AU - Guo, Wei

AU - Dong, Fengqin

AU - Fang, Bingliang

PY - 2006/3/1

Y1 - 2006/3/1

N2 - BACKGROUND. Current treatments for prostate cancer are effective in many patients with locally advanced disease, but many of these patients eventually have recurrence. It is therefore important to develop alternative therapeutic agents with improved efficacy and tolerability. We recently identified a synthetic thiazolidin compound, 5-(2,4-dihydroxybenzylidene)-2-(phenylimino)-1, 3-thiazolidione (DBPT), that induces apoptosis in human colon cancer cells, independent of p53 and P-glycoprotein status. Here, we investigated the antitumor properties and mechanisms of action of this compound in human prostate cancer cell lines. METHODS. The effect of DBPT on cell-cycle progression and apoptosis in LNCaP and DU145 cells was examined by flow cytometry and Western blotting. The effect of DBPT on pro-angiogenic molecules was analyzed by Western blotting and by an enzyme-linked immunosorbent assay. RESULTS. DBPT inhibited the growth of LNCaP and DU145 cells with 50% inhibitory concentrations ranging from 1.6 to 5.9 μM. Treating LNCaP and DU145 cells with DBPT led to a time-dependent cell-cycle arrest in the G2/M phase and increased levels of G2/M checkpoint proteins, such as cyclin B1, cdc25C, phosphorylated histone H3, and MPM-2. DBPT induced the phosphorylation of Bcl-xL and Bim, and induced apoptosis, as evidenced by cleavage of caspase and poly (ADP-ribose) polymerase. DBPT also effectively induced apoptosis in Bcl-2-overexpressing DU145 cells. Furthermore, DBPT decreased hypoxia-inducible factor 1α and vascular endothelial growth factor expression in LNCaP cells under both normoxia and hypoxia. CONCLUSIONS. DBPT can suppress proliferation, induce apoptosis, and downregulate pro-angiogenic molecules in prostate cancercells, and might be useful in treating prostate cancer.

AB - BACKGROUND. Current treatments for prostate cancer are effective in many patients with locally advanced disease, but many of these patients eventually have recurrence. It is therefore important to develop alternative therapeutic agents with improved efficacy and tolerability. We recently identified a synthetic thiazolidin compound, 5-(2,4-dihydroxybenzylidene)-2-(phenylimino)-1, 3-thiazolidione (DBPT), that induces apoptosis in human colon cancer cells, independent of p53 and P-glycoprotein status. Here, we investigated the antitumor properties and mechanisms of action of this compound in human prostate cancer cell lines. METHODS. The effect of DBPT on cell-cycle progression and apoptosis in LNCaP and DU145 cells was examined by flow cytometry and Western blotting. The effect of DBPT on pro-angiogenic molecules was analyzed by Western blotting and by an enzyme-linked immunosorbent assay. RESULTS. DBPT inhibited the growth of LNCaP and DU145 cells with 50% inhibitory concentrations ranging from 1.6 to 5.9 μM. Treating LNCaP and DU145 cells with DBPT led to a time-dependent cell-cycle arrest in the G2/M phase and increased levels of G2/M checkpoint proteins, such as cyclin B1, cdc25C, phosphorylated histone H3, and MPM-2. DBPT induced the phosphorylation of Bcl-xL and Bim, and induced apoptosis, as evidenced by cleavage of caspase and poly (ADP-ribose) polymerase. DBPT also effectively induced apoptosis in Bcl-2-overexpressing DU145 cells. Furthermore, DBPT decreased hypoxia-inducible factor 1α and vascular endothelial growth factor expression in LNCaP cells under both normoxia and hypoxia. CONCLUSIONS. DBPT can suppress proliferation, induce apoptosis, and downregulate pro-angiogenic molecules in prostate cancercells, and might be useful in treating prostate cancer.

KW - Apoptosis

KW - G/M-phase arrest

KW - Novel compound

KW - Prostate cancer

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=33644786231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644786231&partnerID=8YFLogxK

U2 - 10.1002/pros.20373

DO - 10.1002/pros.20373

M3 - Article

C2 - 16302260

AN - SCOPUS:33644786231

VL - 66

SP - 430

EP - 438

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 4

ER -